OncoSec Medical Inc (ONCSQ)

[NY1972]

How strong is ONCS's IP?

We began our current operations as a biotechnology in 2011, following our acquisition of certain assets from Inovio Pharmaceutical, Inc. (“Inovio”). The acquired assets include certain non-DNA vaccine technology and intellectual property relating to selective tumor ablation technologies, a therapy which uses an electroporation device to facilitate delivery of chemotherapy agents, or nucleic acids encoding cytokines, into tumors and/or surrounding tissue for the treatment and diagnosis of various cancers.

On August 24, 2012, we secured an exclusive license for specific patented technology from the University of South Florida Research Foundation relating to the delivery of gene-based therapeutics via intratumoral and intramuscular electroporation. This patent directly supports our clinical development focus in solid tumor applications and specifically metastatic melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma using our ImmunoPulse™ therapy, and extends patent protection for the ImmunoPulse™ technology to the year 2024.